0 item(s)
View cart
You have no items in your shopping cart.
Description
The recombinant humanized anti-CD20 monoclonal antibody is an antibody produced via CHO stable cell line expression system, specifically targeting the CD20 molecule on B-cell surfaces. Through high-affinity binding, it triggers complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP), inducing mitochondrial pathway apoptosis in CD20+ B cells.
In ex vivo B-cell depletion systems, this antibody efficiently eliminates non-Hodgkin lymphoma cells and autoreactive B-cell clones.
Its Fc segment, engineered with glycosylation modifications (e.g., enhanced fucosylation), strengthens binding to FcγRIIIa (V158 variant), significantly enhancing NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC).
In CAR-T therapy development, it serves as an ex vivo B-cell depletion agent to optimize T-cell starting purity and mitigate cytokine release syndrome (CRS) risks by modulating residual B-cell levels.
Manufactured using animal component-free media and affinity chromatography, the product complies with release specifications through stringent control of host protein residuals, host DNA residuals, and endotoxin levels.
It is suitable for B-cell lymphoma immunotherapy, autoimmune disease cell therapies, and bispecific antibody development.
Specifications
| Test Item | Specification | Results |
|---|---|---|
| Appearance | Should be a colorless and transparent liquid | Compliance |
| Identity | The electrophoretic bands should be consistent with the molecular weight of the product | Compliance |
| Visible Particle | Should be no visible particle | Compliance |
| pH | 6.5 – 7.5 | 7.5 |
| Concentration | 1.0 – 1.5 mg/mL | 1.0 mg/mL |
| Purity | >90.0% | Compliance |
| Endotoxin | <0.1 EU/μg | <0.1 EU/μg |
| Mycoplasma | Should be negative | Negative |
| Sterility | No growth | No growth |
Features
-
Recombinant humanized anti-CD20 monoclonal antibody produced in a stable CHO cell expression system, specifically recognizing the CD20 antigen on human B-cell surfaces.
-
High-affinity binding to CD20 efficiently induces B-cell depletion through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP).
-
Fc-mediated effector functions support NK cell-driven ADCC, enabling robust elimination of CD20⁺ target cells in ex vivo systems.
-
Effectively eliminates malignant and autoreactive B-cell populations, supporting downstream immune modulation and functional immune cell enrichment.
-
Manufactured using animal component-free media and affinity chromatography to ensure consistent purity, low host cell residuals, and controlled endotoxin levels.
-
Suitable for research applications requiring reliable and reproducible B-cell targeting in immunology and cell therapy development workflows.
Applications
Ex vivo B-cell depletion
Ex vivo B-cell depletion from PBMCs or mixed immune cell populations.
CD20 cytotoxicity mechanisms
Functional studies of CD20-mediated B-cell cytotoxicity mechanisms.
B-cell malignancy research
Non-Hodgkin lymphoma and B-cell malignancy research.
CAR-T manufacturing support
Removal of residual B cells during CAR-T cell manufacturing to improve T-cell starting purity.
Autoimmune disease research
Autoimmune disease research, including depletion of autoreactive B-cell clones.
Antibody & bispecific strategies
Development and evaluation of antibody-based and bispecific immunotherapy strategies.
Storage
Store at 2–8 °C. Do not freeze. Protect from light.
Documents
Attention
For research and manufacturing purposes only.
When can I expect my order to ship?
Most orders are filled and shipped within 2-3 business days from the time they are received.
Our standard shipping usually take 2-5 days.
We also provide express shippping for time-sensitive deliveries.
Email contact@biofargo.com if you have any requirements.
